FTH - Faeth Therapeutics, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

FTH

FAETH THERAPEUTICS, INC.

NASDAQ

$34.50

▼ DOWN 1.79% (-0.63)

KEY STATISTICS

Market Cap$889.37 M

52w High$42.14

52w Low$7.45

Dividend Yield—

Frequency—

P/E-0.24

Volume2.20M

Shares Out.25.78M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Anand Parikh

COMPENSATION 2026

Salary$481,928

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$644,975

Total$1,260,500

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 4, 2021

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

PRICE TARGET

Target High$70.00

Target Low$50.00

Target Median$58.00

Target Consensus$58.50

UPCOMING EARNINGS

DateNov 13, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2025-06-17	Reverse	1:20

PRICE

$34.50 ▼ DOWN 1.79% (−$0.63)

OVERLAYS

About Faeth Therapeutics, Inc.

https://www.faeththerapeutics.com ↗

Faeth Therapeutics, Inc. is a clinical-stage biotech developing PIKTOR, an oral combination therapy targeting the PI3K/AKT/mTOR pathway to improve cancer patient outcomes through multi-node pathway inhibition.

INDUSTRY

Biotechnology

A PRODUCT FAETH THERAPEUTICS, INC. IS KNOWN FOR

PIKTOR

PIKTOR, developed by Faeth Therapeutics, is an investigational oral combo of serabelisib and sapanisertib targeting the PI3K/AKT/mTOR pathway, currently in clinical trials for endometrial and breast cancer.